Search clinical trials for: BR1017-1B

Total 267 results

Boryung Pharmaceutical Co., Ltd

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy

Type 2 Diabetes Mellitus | Essential Hypertension

Korea, Republic of
Boryung Pharmaceutical Co., Ltd

Recruiting

A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C

Essential Hypertension | Primary Hypercholesterolemia

Korea, Republic of
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administration of "BR1017-1A" and "BR1017-1B"

Essential Hypertension | Primary Hypercholesterolemia

Korea, Republic of
Boryung Pharmaceutical Co., Ltd

Completed

A Clinical Trial to Compare the Pharmacokinetics and Safety of "BR1016C" With "BR1016D" in Healthy Volunteers

Chronic Heart Failure

Korea, Republic of
Boryung Pharmaceutical Co., Ltd

Completed

A Clinical Trial to Compare the Pharmacokinetics and Safety of "BR1016A" With "BR1016B" in Healthy Volunteers

Chronic Heart Failure

Korea, Republic of
Boryung Pharmaceutical Co., Ltd

Recruiting

A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia

Essential Hypertension | Primary Hypercholesterolemia

Korea, Republic of
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fasting Conditions in Healthy Volunteers

Hypertension

Korea, Republic of
Boryung Pharmaceutical Co., Ltd

Completed

A Clinical Trial Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1019-1 and BR1019-2 in Healthy Adult Subjects

Hypertension | Diabetes Mellitus, Type 2

Korea, Republic of
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2"

Type 2 Diabetes Mellitus | Essential Hypertension

Korea, Republic of
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers

Hypertension

Korea, Republic of
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1018-1 and BR1018-2 in Healthy Adult Subjects

Hypertension | Hyperlipidemia (E.G., Hypercholesterolemia)

Korea, Republic of
Boryung Pharmaceutical Co., Ltd

Recruiting

A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy

Essential Hypertension

Korea, Republic of
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

Recruiting

A Phase I Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Orpha Labs

Completed

Study of ORL-1B in Patients With Biotinidase Deficiency

Biotinidase Deficiency
L'Oreal

Completed

Transcriptomic Study of ER 4017 Topical Application in Elderly Subject

Aging

France
Boryung Pharmaceutical Co., Ltd

Completed

A Clinical Trial to Evaluate Drug-drug Interactions and Safety Between "BR1015-1" and "BR1015-2" in Healthy Volunteers

Hypertension

Korea, Republic of
Seno Medical Instruments Inc.

Suspended

Clinical Evaluation of Opto-Acoustic Image Quality With the Gen1B Duplex Probe in Breast Applications

Breast Cancer

United States
Benitec Biopharma, Inc.

Recruiting

A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia

Oculopharyngeal Muscular Dystrophy

United States
S. Andrea Hospital
Italian Multiple Sclerosis Foundation

Completed

Interferon ß-1b Treatment by Cyclical Administration

Multiple Sclerosis

Italy
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Evaluate Drug-drug Interactions Between BR1017-1 and BR1017-2 in Healthy Volunteers

Hypertension | Hypercholesterinemia

Korea, Republic of
Mochida Pharmaceutical Company, Ltd.

Completed

Study Evaluating Single Ascending Doses of MR1817

Adult

United Kingdom
National Cancer Institute (NCI)

Completed

Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

Recurrent Mycosis Fungoides and Sezary Syndrome | Refractory Mycosis Fungoides and Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIIA Mycosis... and other conditions

United States
Aimmune Therapeutics, Inc.

Completed

AR101 Real-World Open-Label Extension Study

Peanut Allergy

United States, Canada
Children's Hospital of Philadelphia
Friedreich's Ataxia Research Alliance; Vidara Therapeutics Research Ltd

Completed

Interferon Gamma-1b in Friedreich Ataxia (FRDA)

Friedreich Ataxia

United States
Aimmune Therapeutics, Inc.

Completed

PALISADE Follow-on Study (ARC004)

Peanut Allergy

United States, Spain, Netherlands, Italy, Canada, Germany, Ireland, Sweden, United Kingdom
Nantes University Hospital

Active, not recruiting

Human Recombinant Interferon Gamma-1b for the Prevention of Hospital-acquired Pneumonia in Critically Ill Patients: a Double-blind, International, Phase 2, Randomized, Placebo-controlled Trial - the PREV-HAP Study (PREV-HAP)

Critically Ill Patients

France, Spain, Greece
Kexing Biopharm Co., Ltd.
The Third Hospital of Changsha; Guoxin Pharmaceutical Technology (Beijing)... and other collaborators

Completed

A Phase I Study in Healthy Participants

Healthy Participants

China
Aimmune Therapeutics, Inc.

Terminated

Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents

Peanut Allergy

Spain
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

Not yet recruiting

Phase I Clinical Study of BR105 Injection (BR105-I)

Advanced Malignancies

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Pharmacokinetic Study of TQB3101 in Chinese Healthy Subjects

Pharmacokinetic Study

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor

Advanced Malignant Tumor

China
Ivix LLX

Completed

BP101 for Adults With Female Sexual Dysfunction

Female Sexual Dysfunction | Hypoactive Sexual Desire Disorder | Sexual Desire Disorder

Russian Federation
Merck KGaA, Darmstadt, Germany
Merck B.V., Netherlands

Terminated

MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS) (MESTRE-MS)

Multiple Sclerosis

Germany
Janssen Research & Development, LLC

Terminated

Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Ivix LLX

Completed

Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire

Hypoactive Sexual Desire Disorder (HSDD)

Russian Federation
Centre Leon Berard
BOIRON

Completed

Evaluation of Homeopathic Treatment for Hot Flashes in Non Metastatic Breast Cancer (HBC)

Breast Cancer

France
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer

Kidney Cancer

United States
Bayer

Terminated

Rehabilitation Study in MS Patients

Multiple Sclerosis, Relapsing-Remitting

France
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

Recruiting

A Phase I Study of BR108 in Hematological Malignancies

Hematologic Malignancy

China
Aimmune Therapeutics, Inc.

Completed

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES) (RAMSES)

Peanut Allergy

United States, Canada
Ivix LLX

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BP101 in Healthy Volunteers

Hypoactive Sexual Desire Disorder(HSDD)

Russian Federation
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics

Advanced Cancer

China
University of North Carolina, Chapel Hill

Completed

Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells

Multiple Sclerosis

United States
BioRay Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies

Advanced Solid Malignancies

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)

Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL)

China
Bayer

Completed

Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis (ROBUST)

Multiple Sclerosis, Relapsing-Remitting

United States
Bayer

Completed

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment (BEACON)

Relapsing Remitting Multiple Sclerosis (RRMS)

China, Slovakia, France, Germany, Korea, Republic of, Saudi Arabia, Singapore, Sweden, Taiwan, Colombia, Czech Republic, Estonia, Italy, Jordan, Lebanon, Mexico, Slovenia, United Kingdom, Argentina, Bahrain, Egypt, United Arab Emirates and more
The Cleveland Clinic
National Cancer Institute (NCI)

Completed

Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma (IFNa)

Melanoma | Sarcoma | Lymphoma | Kidney Cancer | Breast Cancer | Multiple Myeloma | Unspecified Adult Solid Tumor, Protocol Specific

United States
Janssen Research & Development, LLC

Completed

Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

United States

Search clinical trials for: BR1017-1B

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations